The results from this comprehensive, cross-sectional study focusing on 91 PET-imaged multiple sclerosis patients and 1510 lesions demonstrate that in vivo TSPO-PET can be used to quantify innate immune cell activation at chronic lesion edge with subsequent categorization of the lesions into rim-active and rim-inactive lesions. The gene discussed is TSPO; the disease is multiple sclerosis.